EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Therapeutic Use of Cannabis Derivatives and Their Analogs for Autism Spectrum Disorder: A Systematic Review

Rachel Riera iD, Isabela Porto de Toledo iD, Cecília Menezes Farinasso iD, Rafael Leite Pacheco iD, Roberta Borges Silva iD, Verônica Colpani iD, Ana Luiza Cabrera Martimbianco iD, Camila Monteiro Cruz iD, Patrícia do Carmo Silva Parreira iD, Carolina de Oliveira Cruz Latorraca iD

The Journal of Clinical Pharmacology · 2025

DOI: 10.1002/jcph.70068 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift The Journal of Clinical Pharmacology, 2025. Verfasst von Rachel Riera und 9 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Sírio-Libanês (HSL), São Paulo, SP, Brazil. Hauptthemen laut MEDLINE: Autism Spectrum Disorder, Cannabis, Medical Marijuana, Cannabinoids. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Programa de Apoio ao Desenvolvimento Institucional do Sistema Único de Saúde, Ministério da Saúde.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Autism spectrum disorders are characterized by some difficulties with social interactions and communication, atypical patterns of behavior, and unusual reactions to emotions. Studies have found promising results regarding the effects of cannabis on autism. We conducted a systematic review of randomized clinical trials on the effects of cannabis derivatives and their analogs for autism. This review was developed according to the Cochrane Handbook for Systematic Reviews of Interventions and reported according to PRISMA 2020. The protocol was prospectively published in the PROSPERO database (CRD42023468300). We included randomized controlled trials with autism‐diagnosed participants treated with any cannabis derivate or its analogs for therapeutic purposes. Two reviewers assessed titles and abstracts independently and potentially eligible full texts were assessed to confirm eligibility. After that, they extracted data using a standardized worksheet. Searches retrieved 1264 references, only 11 RCTs were included, four with available results for children/adolescents with autism. Five different cannabis presentations were tested. One trial pointed that cannabis may improve global assessment symptoms, but for other outcomes results were uncertain. No included study assessed quality of life. The certainty of evidence ranged from very low to low certainty for the assessed outcomes. Cannabis whole plant extract may improve global assessment symptoms, but the different cannabis presentations, outcome assessments and very low certainty of evidence from the included studies make it difficult to draw conclusions about cannabis for people with autism. This scenario of uncertainties impacts directly clinical practice and decision making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Autism Spectrum DisorderCannabisMedical MarijuanaCannabinoidsHumansRandomized Controlled Trials as TopicChildAdolescent

Stichwörter der Autor:innen

autism spectrum disordersautistic disordercannabidiolcannabismedical marijuanasystematic review

Substanzen

Medical MarijuanaCannabinoids

Autor:innen und Institutionen

  • Hospital Sírio-Libanês (HSL), São Paulo, SP, Brazil.
  • Escola Paulista de Medicina, Universidade Federal de São Paulo (Unifesp), São Paulo, SP, Brazil.
  • Centro Universitário São Camilo (CUSC), São Paulo, SP, Brazil.
  • Universidade Metropolitana de Santos (Unimes), Santos, SP, Brazil.

ORCID-Profile: Rachel Riera, Isabela Porto de Toledo, Cecília Menezes Farinasso, Rafael Leite Pacheco, Roberta Borges Silva, Verônica Colpani, Ana Luiza Cabrera Martimbianco, Camila Monteiro Cruz, Patrícia do Carmo Silva Parreira, Carolina de Oliveira Cruz Latorraca

Förderung

  • Programa de Apoio ao Desenvolvimento Institucional do Sistema Único de Saúde
  • Ministério da Saúde

Zitieren

APA

Riera, R., de Toledo, I. P., Farinasso, C. M., Pacheco, R. L., Silva, R. B., Colpani, V., Martimbianco, A. L. C., Cruz, C. M., Parreira, P. D. C. S., & Latorraca, C. O. C. (2025). Therapeutic Use of Cannabis Derivatives and Their Analogs for Autism Spectrum Disorder: A Systematic Review. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.70068

Vancouver

Riera R, de Toledo IP, Farinasso CM, Pacheco RL, Silva RB, Colpani V, et al. Therapeutic Use of Cannabis Derivatives and Their Analogs for Autism Spectrum Disorder: A Systematic Review. The Journal of Clinical Pharmacology. 2025. doi:10.1002/jcph.70068

BibTeX
@article{Riera2025,
  author = {Riera, Rachel and de Toledo, Isabela Porto and Farinasso, Cecília Menezes and Pacheco, Rafael Leite and Silva, Roberta Borges and Colpani, Verônica and Martimbianco, Ana Luiza Cabrera and Cruz, Camila Monteiro and Parreira, Patrícia do Carmo Silva and Latorraca, Carolina de Oliveira Cruz},
  title = {Therapeutic Use of Cannabis Derivatives and Their Analogs for Autism Spectrum Disorder: A Systematic Review},
  journal = {The Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1002/jcph.70068}
}
Kostenlos starten →